Impairment of medical equipment, CGUs and goodwill

Technology obsolescence, payor contract losses and acquisition-driven goodwill are structural features of the healthcare sector; skipping mandatory annual goodwill testing or using overly optimistic value-in-use assumptions delays recognition of real economic losses, which then surface as large, credibility-damaging impairment charges precisely when the market is already stressed.

Has new technology made existing diagnostic or treatment equipment obsolete, less competitive, or less utilized than planned? Has a branch, service line or cash-generating unit consistently underperformed its business plan or lost a major payor contract, signaling an impairment trigger? Is goodwill allocated to identifiable cash-generating units and tested for impairment at least annually regardless of whether a trigger exists? Is the value-in-use discount rate and cash flow forecast used for testing consistent with the entity's actual budget?

1) Monitor impairment indicators continuously: new-generation technology making equipment obsolete, underperforming branches/service lines versus business plan, loss of a major payor contract, adverse regulatory changes. 2) Test goodwill for impairment at least annually regardless of whether indicators exist, in addition to whenever an indicator arises for other assets. 3) Identify the appropriate cash-generating unit (CGU) level, the smallest identifiable group of assets generating largely independent cash inflows (e.g. a standalone clinic within a hospital network, not the entire network). 4) Allocate goodwill to the CGU(s) expected to benefit from the synergies of the combination that gave rise to it, at the level management actually monitors it. 5) Compare the CGU's carrying amount to its recoverable amount (higher of fair value less costs of disposal and value in use); recognize an impairment loss for any excess, allocated first to goodwill, then pro-rata to other assets in the CGU (not below individual fair value floors). 6) Reverse impairment losses on non-goodwill assets if recoverable amount subsequently increases (up to the depreciated historical cost); never reverse a goodwill impairment.

Estimate value in use using cash flow projections reflecting realistic patient volumes, payor mix and reimbursement rates specific to the clinic or equipment being tested, based on the most recent board-approved budgets/forecasts extrapolated with reasonable, supportable long-term growth assumptions; allocate goodwill to the lowest level of CGUs at which it is monitored for internal management purposes, not an arbitrarily higher aggregation; use a discount rate reflecting current market assessments of the time value of money and risks specific to the CGU, applied on a pre-tax basis to pre-tax cash flows.

Disclose key assumptions used in recoverable amount estimates (discount rate, growth rate, occupancy/utilization rate, payor mix); disclose the amount of any impairment loss or reversal by asset class or CGU and where it is presented in the income statement; disclose goodwill impairment testing results including the CGU(s) goodwill is allocated to and headroom/deficit; disclose sensitivity of the recoverable amount to reasonably possible changes in key assumptions where headroom is not substantial.

• Not testing goodwill annually when no obvious trigger exists, treating the annual test as optional
• using overly optimistic patient volume or reimbursement rate growth assumptions in value-in-use models not supported by approved budgets
• failing to identify the appropriate CGU level (e.g. testing an entire hospital rather than an underperforming standalone clinic within it), masking a localized impairment
• reversing a goodwill impairment loss, which is never permitted
• allocating an impairment loss below the individual fair-value floor of a specific identifiable asset within the CGU.